Artificial Intelligence in Hypertension Management: An Ace up Your Sleeve
Valeria Visco,Carmine Izzo,Costantino Mancusi,Antonella Rispoli,Michele Tedeschi,Nicola Virtuoso,Angelo Giano,Renato Gioia,Americo Melfi,Bianca Serio,Maria Rosaria Rusciano,Paola Di Pietro,Alessia Bramanti,Gennaro Galasso,Gianni D’Angelo,Albino Carrizzo,Carmine Vecchione,Michele Ciccarelli
DOI: https://doi.org/10.3390/jcdd10020074
2023-02-09
Journal of Cardiovascular Development and Disease
Abstract:Arterial hypertension (AH) is a progressive issue that grows in importance with the increased average age of the world population. The potential role of artificial intelligence (AI) in its prevention and treatment is firmly recognized. Indeed, AI application allows personalized medicine and tailored treatment for each patient. Specifically, this article reviews the benefits of AI in AH management, pointing out diagnostic and therapeutic improvements without ignoring the limitations of this innovative scientific approach. Consequently, we conducted a detailed search on AI applications in AH: the articles (quantitative and qualitative) reviewed in this paper were obtained by searching journal databases such as PubMed and subject-specific professional websites, including Google Scholar. The search terms included artificial intelligence, artificial neural network, deep learning, machine learning, big data, arterial hypertension, blood pressure, blood pressure measurement, cardiovascular disease, and personalized medicine. Specifically, AI-based systems could help continuously monitor BP using wearable technologies; in particular, BP can be estimated from a photoplethysmograph (PPG) signal obtained from a smartphone or a smartwatch using DL. Furthermore, thanks to ML algorithms, it is possible to identify new hypertension genes for the early diagnosis of AH and the prevention of complications. Moreover, integrating AI with omics-based technologies will lead to the definition of the trajectory of the hypertensive patient and the use of the most appropriate drug. However, AI is not free from technical issues and biases, such as over/underfitting, the “black-box” nature of many ML algorithms, and patient data privacy. In conclusion, AI-based systems will change clinical practice for AH by identifying patient trajectories for new, personalized care plans and predicting patients’ risks and necessary therapy adjustments due to changes in disease progression and/or therapy response.
cardiac & cardiovascular systems